Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fondaparinux vs low molecular weight heparin for VTE prevention in thrombocytopenia (real-world safety monitoring)
ChiCTR2000039439Phase 4Recruiting
- Sponsor
- Tianjin People's Hospital
- Start
- Dec 2020
- Modality
- Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of fondaparinux in venous thromboembolism (VTE) (2 arms), sponsored by Tianjin People's Hospital. Primary endpoints: 30-day bleeding events and 30-day thrombosis events. Started Dec 2020; status: recruiting.
02
Drugs
fondaparinux
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on ChiCTR2000039439.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000039439.